We have previously demonstrated that TAK1 inhibition by LL-Z1640-2 (LLZ) reduced joint inflammation and bone destruction by inhibiting NLRP3 inflammasome and TNF-α expression in collagen-induced arthritis, a mouse model of rheumatoid arthritis [8]. Here, NLRP3 is linked to rheumatoid arthritis.